In early trading, the shares were 9.9% lower at C$2.10 in Toronto, and are trading down 60% over the last 12 months. On Nasdaq, the shares were 11% weaker at $1.53, for a drop over the last year of 61%. In addition, the FDA requested further information to understand the potential impact of the proposed formulation on immunogenicity risk. Montreal-based Theratechnologies said it plans to address the FDA's request and intends to pursue approval of this newer formulation of tesamorelin. Write to Robb M. Stewart at robb.stewart@wsj.com and Colin Kellaher at colin.kellaher@wsj.com(END) Dow Jones NewswiresJanuary 24, 2024 10:32 ET (15:32 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal January 24, 2024 15:42 UTC